Leritrelvir

来瑞特韦

Report date: 2025/09/11 15:54:21
NME

Base Information

Drug NameLeritrelvir
Drug Alias Name乐睿灵RAY-1216RAY003RAY-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acute Kidney InjuryHepatic Insufficiency
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2023/03/23
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangdong Raynovent Biotech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangdong Raynovent Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Acute Kidney InjuryHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A